

P0034-2025

ספרות מחייבת לבחינת סיום התמחות - מחלות ריאה ילדים

BOOKS

1. Albert Li & Heather Zar & Peter Sly & Felix Ratjen & Robin R Deterding & Andrew Bush & Kendig's Disorders of the Respiratory Tract in Children, **10th Edition**. Robert W. Wilmott.
2. West's Respiratory Physiology: The Essentials (English)-**11th Edition**. John B. West MD PhD DSc, Andrew M. Luks MD JOURNALS

רשימת מאמרים :

1. Nirsevimab for prevention of Hospitalization due to RSV in infants. NEJM 2023
2. Nirsevimab and Hospitalization for RSV Bronchiolitis. NEJM 2024
3. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. NEJM 2023
4. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. NEJM 2025
5. Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicenter, double-blind, randomized, placebo-controlled trial. Lancet Respir Med 2024
6. Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicenter, double-blind, randomized, placebo-controlled trial. NEJM 2025
7. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele. AJRCCM 2023
8. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med 2025
9. The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant. ERJ 2023

10. The new biologic drugs. Which children with asthma should get what? Ped Pul 2024
11. Radiographic outcomes in pediatric bronchiectasis and factors associated with reversibility. AJRCCM 2024
12. Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20–121-102 and VX20–121-103): results from two randomized, active-controlled, phase 3 trials. Lancet Respir Med 2025
13. Pediatric Adenotonsillectomy trial for snoring (pats) study team.
Adenotonsillectomy for snoring and mild sleep apnea in children. A randomized clinical trial. JAMA 2023
14. Early detection and treatment of obstructive sleep apnea in infants with Down syndrome A prospective non-randomized controlled interventional study. Lancet 2024
15. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Lancet 2023
16. Impact of early LRTI on lifelong lung function. Lancet child adolescent health 2023
17. Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. JAMA 2020
18. Long-Term Efficacy of House Dust Mite Sublingual Immunotherapy on Clinical and Pulmonary Function in Patients With Asthma and Allergic Rhinitis. Free. JACI 2024
19. As-Needed Albuterol–Budesonide in Mild Asthma. NEJM 2025
20. Early-life RSV and long-term respiratory health. Lancet 2024
21. Efficacy of Tezepelumab in Patients With Evidence of Severe Allergic Asthma: Results From the Phase 3 NAVIGATOR Study. Pediatrics 2023
22. Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. ERJ 2024
23. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. ERJ 2023
24. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. JACI practice 2024
25. Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study. Ped Pul 2024.

26. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024.
27. Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children. JAMA Pediatr. 2025 Apr 1; 179(4): 418-427.